Mike has over 35 years of UK and Global pharmaceutical industry experience within the field of antibiotics, antimicrobial resistance and infectious disease. Mike started his career as a clinical pharmacologist working with the Pain & Opiate Research Group at the Nuffield Department of Anaesthetics in Oxford from 1979 to 1986, obtaining his DPhil in 1986.
In January 1987 he joined Lederle Laboratories (later became Wyeth Pharmaceuticals) where he was responsible for the Medical activities for piperacillin/tazobactam throughout its lifecycle and the pre and post launch Medical activities for tigecycline from 2003 – 2007. Mike joined Novartis Pharmaceuticals in 2007 as the Medical Development Advisor for antibiotics, with the medical responsibilities for daptomycin, inhaled tobramycin and pipeline antibiotics, for the UK and Region Europe. In February 2015 he joined Cubist Pharmaceuticals, before moving to MSD in April following the acquisition of Cubist by MSD.
Mike currently works as the Regional Medical Advisor (Antibiotics) and MSD Ltd UK, with medical responsibilities for MSD’s broad portfolio of licensed antibiotics and pipeline molecules. Over his career in the pharmaceutical industry, he has worked collaboratively with the medical, commercial, policy and development teams at National, European and Global levels, including the coordination of a highly successful international antibiotic registry and multiple clinical and in vitro antibiotic studies.
Mike was elected to serve a 3-year term as General Secretary of BSAC in May 2022 and has been an Ordinary Member of BSAC Council since 2018, having previously served as an Ordinary Member of Council from 2012-2015. He is a core member of the BSAC Resistance Surveillance Project Legacy Working Group, having served on the Steering Committee since the inception of the project in 1999, both as an industry representative and core member. Mike has been a member of the Antibiotic Research UK (ANTRUK) Scientific Committee since 2018.
Mike has co-authored over 40 publications with lead researchers in the UK and internationally, looking particularly at antibiotic resistance surveillance and the association between antibiotic use and infections caused by clinically significant pathogens including; Clostridium difficile, glycopeptide-resistant enterococci, MRSA, Pseudomonas aeruginosa and ESBL-producing Enterobacteriales.